– Second Synthetic Biotic™ program to move into clinical studies in 2018 – – SAD/MAD study will include healthy volunteers and expansion cohorts of adult patients with PKU – – Interim data expected in 2018; full data in 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr.
– Data highlight the application of Synthetic Biotic medicines for the potential treatment of a variety of solid tumors – – Company is advancing the first candidate from this program into IND-enabling studies in 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 6, 2018-- Synlogic, Inc. (Nasdaq: SYBX) , a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced that it has agreed to sell 3,280,000 shares of its common stock to a large mutual fund investor in
– First clinical trial of a Synthetic Biotic ™ Medicine in patients – – Randomized, double-blind, placebo-controlled study evaluating safety and tolerability of SYNB1020 as primary endpoint; ammonia-lowering as secondary endpoint – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 21, 2018-- Synlogic (Nasdaq:SYBX) announced today that JC Gutiérrez-Ramos, Ph.D., Synlogic’s president and chief executive officer, will present a corporate update at the 17 th Annual Needham Healthcare Conference at 12:15 p.m.
– Strengthened balance sheet with $53.7M public offering; extended cash runway through 2019 – – Initiated Phase 1b/2a study evaluating SYNB1020 in patients with cirrhosis and hyperammonemia; topline data expected in 4Q 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 20, 2018-- Synlogic, Inc.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 19, 2018-- Synlogic, Inc. , (Nasdaq: SYBX ) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that preclinical data from its immuno-oncology (IO) program will
– Expanded clinical data set from Phase 1 study confirms proof of mechanism and supports continued development of SYNB1020 for treatment of hyperammonemia – – A Phase 1b / 2a clinical trial to further evaluate SYNB1020 is open and screening patients – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2018-- Synlogic (Nasdaq:SYBX) announced today that JC Gutiérrez-Ramos, Ph.D., Synlogic’s president and chief executive officer, will present a corporate update at the Cowen and Company 38th Annual Health Care Conference at 3:30 p.m.
- Data presented at Keystone Symposium demonstrate rapid tumor rejection in preclinical models - - Data support advancement of Synthetic Biotic medicines as potential immuno-therapies for cancer - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 13, 2018-- Synlogic ( Nasdaq: SYBX ), a clinical-stage
